Cargando…

An Overview of CD133 as a Functional Unit of Prognosis and Treatment Resistance in Glioblastoma

Biomarkers for resistance in Glioblastoma multiforme (GBM) are lacking, and progress in the clinic has been slow to arrive. CD133 (prominin-1) is a membrane-bound glycoprotein on the surface of cancer stem cells (CSCs) that has been associated with poor prognosis, therapy resistance, and tumor recur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joyce, Thomas, Jagasia, Sarisha, Tasci, Erdal, Camphausen, Kevin, Krauze, Andra Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528301/ https://www.ncbi.nlm.nih.gov/pubmed/37754516 http://dx.doi.org/10.3390/curroncol30090601

Ejemplares similares

Cost Matrix of Molecular Pathology in Glioma—Towards AI-Driven Rational Molecular Testing and Precision Care for the Future
por: Jagasia, Sarisha, et al.
Publicado: (2022)

GradWise: A Novel Application of a Rank-Based Weighted Hybrid Filter and Embedded Feature Selection Method for Glioma Grading with Clinical and Molecular Characteristics
por: Tasci, Erdal, et al.
Publicado: (2023)

RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma
por: Tasci, Erdal, et al.
Publicado: (2023)

SDPS-29 SERUM-DERIVED CD47 AS A MARKER OF TUMOR BURDENAND OUTCOME IN GBM PATIENTS – CORRELATIVE ANALYSISOF TUMOR LOCATION, RADIATION THERAPY VOLUMES,AND SURVIVAL
por: Jagasia, Sarisha, et al.
Publicado: (2023)

CLRM-04 DEVELOPING A WORD LEXICON FOR VENOUS THROMBOEMBOLISM DATA ANNOTATION USING RADIOLOGY REPORTS IN GLIOBLASTOMA PATIENTS - LINKING LARGE-SCALE DATA SETS TO EXPAND CLINICAL FEATURES FOR AI
por: Jagasia, Sarisha, et al.
Publicado: (2023)

Hierarchical Voting-Based Feature Selection and Ensemble Learning Model Scheme for Glioma Grading with Clinical and Molecular Characteristics
por: Tasci, Erdal, et al.
Publicado: (2022)

Bias and Class Imbalance in Oncologic Data—Towards Inclusive and Transferrable AI in Large Scale Oncology Data Sets
por: Tasci, Erdal, et al.
Publicado: (2022)

The Next Frontier in Health Disparities—A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back
por: Diaz Rosario, Maria, et al.
Publicado: (2022)

Glioblastoma survival is associated with distinct proteomic alteration signatures post chemoirradiation in a large-scale proteomic panel
por: Krauze, Andra Valentina, et al.
Publicado: (2023)

Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation
por: Krauze, Andra V., et al.
Publicado: (2023)

Molecular Biology in Treatment Decision Processes—Neuro-Oncology Edition
por: Krauze, Andra V., et al.
Publicado: (2021)

AI-Driven Image Analysis in Central Nervous System Tumors-Traditional Machine Learning, Deep Learning and Hybrid Models
por: Krauze, AV, et al.
Publicado: (2022)

A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells
por: Ahmed, Eroje M., et al.
Publicado: (2018)

Chemoirradiation for Glioblastoma Multiforme: The National Cancer Institute Experience
por: Ho, Jennifer, et al.
Publicado: (2013)

CD133 Expression in Glioblastoma Multiforme: A Literature Review
por: Ahmed, Syed Ijlal, et al.
Publicado: (2018)

Analytical Considerations of Large-Scale Aptamer-Based Datasets for Translational Applications
por: Jiang, Will, et al.
Publicado: (2022)

Bringing the heavy: carbon ion therapy in the radiobiological and clinical context
por: Schlaff, Cody D, et al.
Publicado: (2014)

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression
por: Perazzoli, Gloria, et al.
Publicado: (2015)

Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme
por: Brown, Daniel V., et al.
Publicado: (2015)

Analysis of gene expression and chemoresistance of CD133(+ )cancer stem cells in glioblastoma
por: Liu, Gentao, et al.
Publicado: (2006)

Mesenchymal stem cell-like properties of CD133(+) glioblastoma initiating cells
por: Pavon, Lorena Favaro, et al.
Publicado: (2016)

Preferential Association of Lissencephaly-1 Gene Expression with CD133+ Glioblastoma Cells
por: Brehar, Felix Mircea, et al.
Publicado: (2017)

CD133 Regulates IL-1β Signaling and Neutrophil Recruitment in Glioblastoma
por: Lee, Seon Yong, et al.
Publicado: (2017)

Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM)
por: Krauze, Andra V, et al.
Publicado: (2013)

CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma
por: Fan, Linni, et al.
Publicado: (2011)

Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme
por: Kase, Marju, et al.
Publicado: (2013)

Selective Lentiviral Gene Delivery to CD133-Expressing Human Glioblastoma Stem Cells
por: Bayin, N. Sumru, et al.
Publicado: (2014)

Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system
por: Krauze, Andra Valentina, et al.
Publicado: (2017)

Malignant behaviorial characteristics of CD133(+/−) glioblastoma cells from a Northern Chinese population
por: LIU, XIAOZHI, et al.
Publicado: (2013)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

CD133 and Ki-67 expression is associated with gastrointestinal stromal tumor prognosis
por: LU, CANRONG, et al.
Publicado: (2013)

Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma
por: Park, Youn Young, et al.
Publicado: (2019)

CD133 expression in chemo-resistant Ewing sarcoma cells
por: Jiang, Xiaohua, et al.
Publicado: (2010)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)

Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients
por: Minajeva, Ave, et al.
Publicado: (2017)

CD133 Expression and the Prognosis of Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Shicai, et al.
Publicado: (2013)

Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer
por: Hashimoto, Kousuke, et al.
Publicado: (2013)

Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer
por: Pradhan, Tapas, et al.
Publicado: (2019)

Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma
por: Zhang, Jie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lv61ed1hr8hmp16umddil5q18n